Affordable CAR-T breakthrough: academic therapy offers new hope for blood cancer patients
NCT ID NCT07524816
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a more affordable version of CAR-T cell therapy for people with relapsed or hard-to-treat large B-cell lymphoma. The treatment uses the patient's own immune cells, modified to attack cancer cells. The goal is to see if this academic-made therapy works as well as expensive commercial versions, making it more accessible to patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA (LBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NN Alexandrov National Cancer Centre of Belarus
RECRUITINGLyasny, Minsk Oblast, 223040, Belarus
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI takes on lymphoma: personalized drug cocktail aims to outsmart cancer in older patients
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Automated CAR-T therapy shows promise for Tough-to-Treat lymphoma
- New hope: drug may prevent dangerous reactions to cancer immunotherapy
- New hope for lymphoma patients: glofitamab combo faces standard care in trial
- AI takes on lymphoma: personalized treatment strategy under trial